Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ipatasertib by Genentech USA for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase III for Human Epidermal Growth Factor Receptor 2...
Ipatasertib by Genentech USA for Metastatic Breast Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase III for Metastatic Breast Cancer. According to GlobalData,...
Ipatasertib by Genentech USA for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
Ipatasertib by Genentech USA for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Oral Cavity (Mouth) Cancer. According to...
Ipatasertib by Genentech USA for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Paranasal Sinus And Nasal Cavity Cancer....
Ipatasertib by Genentech USA for Oropharyngeal Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Oropharyngeal Cancer. According to GlobalData, Phase...
Ipatasertib by Genentech USA for Laryngeal Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Laryngeal Cancer. According to GlobalData, Phase...
Ipatasertib by Genentech USA for Hypopharyngeal Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Roche's Ipatasertib?
Ipatasertib is a small molecule commercialized by Roche, with a leading Phase III program in Metastatic Breast Cancer;Human Epidermal Growth...